PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: The Netherlands

PE Guidelines
Guideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)
PDF in Dutch
PDF in English

PE Guidelines Source:
National Health Care Institute (ZIN)
http://www.zorginstituutnederland.nl

Additional Information:
Costing Manual
PDF in Dutch

Manual on Quality of Life Measurements
PDF in Dutch

Uncertainty and Value of Information
PDF in English

Last Webpage Update: Monday, January 15, 2018

PE Guidelines Key Features:

Key Features:  
Title and year of the documentGuideline for the Conduct of Economic Evaluations in Health Care (Dutch Version February 2016)   
Affiliation of authorsNational Health Care Institute 
Purpose of the documentProviding guidance for conduct of EE studies for reimbursement issues in order to improve their quality, credibility and comparability 
Standard reporting format includedYes 
DisclosureYes 
Target audience of funding/ author's interestsWho conduct economic evaluations or evaluate the economic evaluations studies (decision makers) 
PerspectiveSocietal perspective. Report unrelated medical costs in life years gained seperately.  
IndicationApproved indication; although sometimes off-label use is considered for comparator  
Target populationBe clearly specify 
Subgroup analysisYes 
Choice of comparatorStandard of care or usual care in the Netherlands 
Time horizonLife time 
Assumptions requiredYes 
Preferred analytical techniqueCUA  
Costs to be includedSocietal perspective. Report unrelated medical costs in life years seperately. 
Source of costsReference prices list should be used 
ModelingYes, requires details 
Systematic review of evidencesYes, encourage meta-analysis 
Preference for effectiveness over efficacyYes, modelling on trial data and other sources is required  
Preferred outcome measureQALY and optional other measures of effectiveness like life years gained (LYG)  
Preferred method to derive utilityEQ-5D-5L using Dutch value set  
Equity issues statedYes 
Discounting costs4% 
Discounting outcomes1.5% 
Sensitivity analysis-parameters and rangeAll key uncertain parameters, within a defined area and best/worst case scenario 
Sensitivity analysis-methodsOne-way, multi-way or scenario and probabilistic analysis 
Presenting resultsMust be clear. Total costs and effects, incremental costs and effects. Results sensitivity analysis in tables and appropriate figures 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)Study must refer to national context; utilities preferable calculated using Dutch value sets  
Financial impact analysisYes 
Mandatory or recommended or voluntaryMandatory 

Acknowledgement: Saskia Knies, PhD, Pharmacoeconomics Advisor, Zorginstituut Nederland (ZIN), Diemen, The Netherlands and Maarten J. IJzerman, PhD, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

Country Selection Page | PE Guidelines Index Page